Full Press Release Details
For much of modern cardiology, success has often been measured in immediate terms.
Did the chest pain improve? Did the rhythm stabilize? Did the patient make it safely through the acute episode?
These outcomes matter deeply. They save lives. They relieve suffering.
But increasingly, researchers and clinicians are asking a more fundamental question:
Are we changing the disease itself — or simply managing its symptoms?
That distinction is becoming one of the most important shifts underway in cardiovascular medicine.
What Is Symptom Management?
Symptom management focuses on relieving the immediate effects of disease.
In cardiology, this can mean: • Reducing chest pain • Controlling inflammation temporarily • Managing arrhythmias • Supporting heart function during stress or injury
These approaches are essential. They stabilize patients and prevent short-term complications. But in many conditions, they do not necessarily address the biological mechanisms driving the disease.
When treatment is reduced or stopped, symptoms may return. The underlying process may still be active.
What Is Disease Modification?
Disease modification is a different goal.
Rather than focusing solely on relieving symptoms, disease-modifying therapies aim to: • Alter the underlying biological process • Reduce ongoing tissue injury • Change the long-term trajectory of the condition • Support more durable recovery
In other therapeutic areas, this shift has already transformed care. In autoimmune diseases, for example, understanding immune pathways led to treatments designed to modify disease activity, not just ease flare-ups.
Cardiology is increasingly entering a similar phase.
Why This Shift Matters in Inflammatory Heart Disease
In conditions such as pericarditis and myocarditis, inflammation is a central driver in the initiation and progression of disease.
When inflammation persists or recurs, it can: • Cause repeated injury to cardiac tissue • Trigger structural changes in the heart • Increase the risk of long-term complications • Disrupt patients’ quality of life through cycles of relapse
If treatment focuses only on symptom relief, the inflammatory process may continue beneath the surface.
But if therapies can more directly and durably address inflammation itself, the possibility emerges for moving beyond managing episodes to truly altering the course of disease.
Recovery Is More Than Stabilization
This distinction is especially important in myocarditis.
In the acute phase, stabilizing heart function is critical. But once inflammation settles, another question becomes central:
Has the heart truly recovered?
Structural changes (including enlargement, reduced pumping function or scarring) can persist even after symptoms improve.
Disease-modifying approaches aim to reduce not only the immediate inflammatory injury, but also its downstream structural consequences.
That shift from stabilization to recovery represents a meaningful evolution in how outcomes are evaluated.
The Broader Evolution of Cardiology
The practice of cardiology is gaining better ways to measure disease activity and structural change with advancements in imaging tools and new biomarkers.
This allows for an improved understanding of what meaningful progress looks like.
Rather than focusing only on symptom reduction, researchers can now assess changes in cardiac structure, markers of inflammation, rates of recurrence and durability of response over time.
This evolution is creating space for therapies designed with disease modification in mind.
How Cardiol Approaches This Shift
At Cardiol Therapeutics, our work is grounded in the knowledge that inflammation is a key mechanism in heart disease.
If inflammation is driving disease activity, recurrence, and structural injury, then addressing it directly becomes essential.
Our clinical programs are designed not only to evaluate symptom improvement, but also to assess meaningful biological and structural outcomes.
This reflects a broader goal: to contribute to durable control of disease processes and disease recovery.
Why This Matters for Patients
For patients, the difference between symptom management and disease modification is not abstract.
It can mean fewer recurrences, reduced long-term heart damage, and more confidence in returning to work, exercise, and daily life.
As understanding deepens, the ambition in cardiovascular care is evolving. The goal is no longer only to help patients get through an episode – but to help change what happens next.
As inflammation becomes better understood as a disease driver, the opportunity grows to design therapies that address it; one’s that may help reshape the trajectory of disease itself.
That shift from managing consequences to modifying mechanisms has the potential to define the next era in cardiovascular medicine.